MDGL - NASDAQ
Madrigal Pharmaceuticals, Inc.
$488.15
+7.8%Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
At a Glance
Live Snapshotmdgl
Total Non-Current Liabilities
Last Annual Value
346.61M
3-Year CAGR
92%
5-Year CAGR
275%
10-Year CAGR
%
Madrigal Pharmaceuticals, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL | 346.61M | 43.8% | 289.4% | N/A | |
 Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM | 236.18M | 29.9% | 161.1% | 94.1% | |
 Caris Life Sciences, Inc. NASDAQ:CAI | 421.21M | -44.5% | N/A | -11.5% | |
 Atrium Therapeutics, Inc. NASDAQ:RNA | 29.27M | -14.7% | 12.2% | N/A | |
 Moderna, Inc. NASDAQ:MRNA | 1.70B | 3.0% | 4.0% | 15.2% | |
 Exelixis, Inc. NASDAQ:EXEL | 277.46M | -0.8% | 32.5% | 1.6% | |
 Baxter International Inc. NYSE:BAX | 10.98B | -6.2% | -11.4% | 9.3% | |
 Jazz Pharmaceuticals plc NASDAQ:JAZZ | 5.10B | -5.9% | -7.5% | 6.7% | |
 BioMarin Pharmaceutical Inc. NASDAQ:BMRN | 747.99M | 1.6% | -8.9% | -0.9% | |
 Bio-Techne Corporation NASDAQ:TECH | 463.21M | -5.2% | -3.0% | 9.0% |
Madrigal Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your MDGL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.